United States - English - NLM (National Library of Medicine)

bryant ranch prepack - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - metoclopramide tablets are indicated for the: - treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. - relief of symptoms in adults with acute and recurrent diabetic gastroparesis. limitations of use : metoclopramide tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (td) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [see use in specific populations ( 8.4) ]. metoclopramide is contraindicated: - in patients with a history of tardive dyskinesia (td) or a dystonic reaction to metoclopramide [see warnings and precautions ( 5.1, 5.2) ]. - when stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). - in patients with pheochromocytoma or other catecholamine-releasing paragangliomas. metoclopramide may cause a hypertensive/pheochromocyt

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide tablets, usp is recommended for adults only. therapy should not exceed 12 weeks in duration. symptomatic gastroesophageal reflux metoclopramide tablets, usp are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12 week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. diabetic gastr

United States - English - NLM (National Library of Medicine)

carilion materials management - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg - the use of metoclopramide tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12 week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide tablets are indicated for the relief of sympt

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg in 5 ml - the use of metoclopramide oral solution is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide oral solution usp is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide is indicated for the relief of

United States - English - NLM (National Library of Medicine)

unit dose services - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg in 5 ml - the use of metoclopramide oral solution is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide oral solution usp is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide is indicated for the relief of

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. symptomatic gastroesophageal reflux: metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. diabetic gastroparesis

United States - English - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg - the use of metoclopramide   tablets, usp is recommended for adults only. therapy should not exceed 12 weeks in duration. symptomatic gastroesophageal reflux:  metoclopramide tablets, usp are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopic

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - metoclopramide hydrochloride - solution for injection - metoclopramide hydrochloride 5 mg/ml - metoclopramide - metoclopramide s.a.l.f 10 mg/2 ml is indicated in adults for: - prevention of postoperative nausea and vomiting (ponv) - prevention of delayed nausea and vomiting caused by chemotherapy (delayed cinv) - prevention of nausea and vomiting caused by radiation therapy - symptomatic treatment of nausea and vomiting, including nausea and vomiting caused by migraine attack. in migraine attacks, metoclopramide can be used concomitantly with oral analgesics to improve their absorption. - diabetic gastroparesis - to faciliate diagnostic procedures (ie, to faciliate small bowel intubation and as an aid in radiological examinations) pediatric population. metoclopramide s.a.l.f 10 mg/2 ml is indicated in children aged 1 to 18 years for: - second line-therapy: treatment of established postoperative nausea and vomiting (ponv) - second-line therapy: prevention of delayed nausea and vomiting caused by chemotherapy (delayed cinv) - to facilitate diagnostic procedures (ie, to faciliate small bowel intubation and as an aid in radiological examinations).

New Zealand - English - Medsafe (Medicines Safety Authority)

lumacina new zealand - metoclopramide hydrochloride monohydrate 5.27 mg/ml equivalent to metoclopramide hydrochloride 5 mg/ml - solution for injection - 10 mg/2ml - active: metoclopramide hydrochloride monohydrate 5.27 mg/ml equivalent to metoclopramide hydrochloride 5 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - adults (20 years and over) · relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy or radiation), malignant disease, labour, infectious disease and uraemia · control of post-operative vomiting · assist in small bowel intubation metoclopramide is of little benefit for the prevention or treatment of motion sickness. young adults and children (over 1 year of age) metoclopramide should be restricted to the following conditions and only used as second line therapy, when used to treat children and young adults under 20 years of age because of the risk of adverse effects. · severe intractable vomiting of known cause · vomiting associated with radiation therapy or intolerance to cytotoxic drugs · assist in small bowel intubation

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - metoclopramide hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium hydroxide; hydrochloric acid; water for injections; nitrogen; sodium chloride - adults (20 years or older): - relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy or radiation), malignant disease, labour, infectious disease and uraemia. - control of post-operative vomiting - assist in small bowel intubation.,metoclopramide is of little benefit for the prevention or treatment of motion sickness.,young adults and children (over 1 year of age): metoclopramide should be restricted to the following conditions and only used as second line therapy, when used to treat children and young adults under 20 years of age because of the risk of adverse effects - severe intractable vomiting of known cause - vomiting associated with radiation therapy or intolerance to cytotoxic drugs. - assist in small bowel intubation